-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Linkco Pharmaceuticals (Hangzhou) Co.
, Ltd.
(hereinafter referred to as “Linkco Pharmaceuticals”) is an innovative drug research and development company in the clinical stage
.
The company recently announced that the first patient has been dosed in a Phase II clinical trial of its selective JAK1 inhibitor LNK01001 for the treatment of autoimmune diseases in atopic dermatitis (AD)
.
This study is a clinical study evaluating the efficacy and safety of LNK01001 capsules in adult patients with moderate to severe atopic dermatitis
.
Atopic dermatitis is a chronic, relapsing, inflammatory skin disease that often occurs on the face, neck, and elbow fossa
.
Patients with moderate-to-severe atopic dermatitis have recurrent severe itching and chronic eczema-like skin lesions as the main clinical manifestations, and are often combined with other atopic diseases such as allergic rhinitis and asthma, which seriously affect the quality of life
.
LNK01001 is a new class 1 drug independently developed by Lingke Pharmaceuticals for the treatment of autoimmune diseases.
It is currently in the clinical development stage.
Previously, clinical phase II studies for rheumatoid arthritis and ankylosing spondylitis have been carried out.
.
The lead researcher of the study, Professor Zhang Jianzhong, director of the 13th session of the Dermatology Branch of the Chinese Medical Association, and director of the Department of Dermatology of Peking University People's Hospital, said: "Atopic dermatitis is a chronic disease, and the disease is often protracted and unhealed.
It seriously affects the quality of life of patients, and also brings a huge burden and mental pressure to the patient's family and society; LNK01001 has shown good safety in the trial of healthy people, and we expect excellent efficacy and safety in the trial of patients
.
" Dr.
Xueli Wang, Chief Medical Officer of Lingke Pharmaceutical, said: "Atopic dermatitis has profound negative impacts on the physical and mental health and economy of patients and their families, and it requires long-term disease management
.
LNK01001 is a very promising treatment for atopic dermatitis.
As an innovative drug candidate for autoimmune diseases such as dermatitis, we will target the needs of patients and work with researchers to rapidly advance the clinical research of LNK01001 to benefit patients as soon as possible
.
"
, Ltd.
(hereinafter referred to as “Linkco Pharmaceuticals”) is an innovative drug research and development company in the clinical stage
.
The company recently announced that the first patient has been dosed in a Phase II clinical trial of its selective JAK1 inhibitor LNK01001 for the treatment of autoimmune diseases in atopic dermatitis (AD)
.
This study is a clinical study evaluating the efficacy and safety of LNK01001 capsules in adult patients with moderate to severe atopic dermatitis
.
Atopic dermatitis is a chronic, relapsing, inflammatory skin disease that often occurs on the face, neck, and elbow fossa
.
Patients with moderate-to-severe atopic dermatitis have recurrent severe itching and chronic eczema-like skin lesions as the main clinical manifestations, and are often combined with other atopic diseases such as allergic rhinitis and asthma, which seriously affect the quality of life
.
LNK01001 is a new class 1 drug independently developed by Lingke Pharmaceuticals for the treatment of autoimmune diseases.
It is currently in the clinical development stage.
Previously, clinical phase II studies for rheumatoid arthritis and ankylosing spondylitis have been carried out.
.
The lead researcher of the study, Professor Zhang Jianzhong, director of the 13th session of the Dermatology Branch of the Chinese Medical Association, and director of the Department of Dermatology of Peking University People's Hospital, said: "Atopic dermatitis is a chronic disease, and the disease is often protracted and unhealed.
It seriously affects the quality of life of patients, and also brings a huge burden and mental pressure to the patient's family and society; LNK01001 has shown good safety in the trial of healthy people, and we expect excellent efficacy and safety in the trial of patients
.
" Dr.
Xueli Wang, Chief Medical Officer of Lingke Pharmaceutical, said: "Atopic dermatitis has profound negative impacts on the physical and mental health and economy of patients and their families, and it requires long-term disease management
.
LNK01001 is a very promising treatment for atopic dermatitis.
As an innovative drug candidate for autoimmune diseases such as dermatitis, we will target the needs of patients and work with researchers to rapidly advance the clinical research of LNK01001 to benefit patients as soon as possible
.
"